Extended Depth of Focus (EDF) Intraocular Lens (IOL) Versus Monofocal Intracoular Lens (IOL)

Inclusion Criteria:

1. Patients of any gender, aged 18 years or older

2. Patient with clinically significant bilateral age-related cataracts planned forphacoemulsification cataract extraction and eligible for implantation of a posteriorchamber intraocular lens as determined by investigator's medical judgement

3. Preoperative keratometric (corneal) astigmatism of 1.00 D or less (≤1.00 D)

4. Calculated lens power within the available range

5. Clear intraocular media other than cataract

6. Patient is willing and capable of providing informed consent

7. Patient is willing and capable of complying with visits and procedures as defined bythis protocol

Exclusion Criteria:

1. Preoperative corrected distance visual acuity (CDVA) better than 0.3 logMAR (0.5decimal)

2. Endothelial cell count of less than 2000/mm2

3. Acute, chronic, or uncontrolled systemic disease that could increase the operativerisk or confound the outcome including but not limited to poorly controlled diabetesmellitus, active cancer treatment, mental illness, dementia, immunocompromised,connective tissue disease, clinically significant atopic disease, etc.

4. Ocular condition that may predispose patient to future complications, perinvestigator's medical judgement, including but not limited to severe dry eye,anterior segment pathology, uncontrolled glaucoma, that would result in a visualacuity of 0.2 logMAR or worse during the study

5. Clinically significant corneal abnormalities, including corneal dystrophy (epithelial, stromal or endothelial dystrophy), irregularity or oedema as perInvestigator's medical judgement; conditions including but not limited tokerato-uveitis, keratopathy, keratectasia

6. Previous intraocular or corneal/refractive surgery that might confound the outcomeof the investigation or increase the risk to the patient (including cornealtransplants, removal of pterygium, and LASIK, LASEK, PRK, RK limbal relaxingincision etc.)

7. Any clinically significant condition that could affect IOL stability (e.g. zonulardialysis, evident zonular weakness or dehiscence, etc.)

8. Patients with diagnosed degenerative visual disorders (e.g. macular degeneration orother retinal disorders, optic nerve atrophy etc.) or any other pathologies of theeye that are predicted to result in a visual acuity of 0.2 logMAR or worse duringthe study

9. Current systemic or ocular pharmacotherapy that effects patients' vision withsignificant ocular side effects or any medications that could confound the outcomeor increase subject risk

10. Clinically significant gonioscopic abnormalities

11. Amblyopia, strabismus, single eye status

12. Rubella, congenital, traumatic or complicated cataracts

13. History of or current anterior or posterior segment inflammation, including but notlimited to iritis or uveitis

14. Microphthalmos or macrophthalmos

15. Pupil abnormalities (e.g. aniridia, abnormal shaped pupils, nonreactive pupils)

16. Pseudoexfoliation

17. Keratoconus or irregular astigmatism

18. Inability to measure keratometry or biometry (including but not limited to cataractdensity, etc.)

19. Pathologic miosis

20. Pregnant, plan to become pregnant, lactating during the course of the investigation,or another condition with associated fluctuation of hormones that could lead torefractive changes

21. Patients unable to meet the limitations of the protocol or likely of non-cooperationduring the trial

22. Patients whose freedom is impaired by administrative or legal order

23. Concurrent participation in another clinical investigation in the last 30 days.